U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Non-Hodgkin lymphoma(NHL)

MedGen UID:
6160
Concept ID:
C0024305
Neoplastic Process
Synonyms: LYMPHOMA, NON-HODGKIN, SOMATIC; Malignant lymphoma, non-Hodgkin; NHL
SNOMED CT: Malignant lymphoma, non-Hodgkin's type (118601006); Non-Hodgkin's lymphoma - disorder (118601006); NHL - Non-Hodgkin's lymphoma (118601006); Non-Hodgkin's lymphoma (clinical) (118601006); Non-Hodgkin's lymphoma (118601006); Non-Hodgkin lymphoma (118601006); Diffuse non-Hodgkin's small cleaved cell (diffuse) lymphoma (188675007); Malignant lymphoma, non-Hodgkin (1172592001); Diffuse malignant lymphoma (1172592001); Malignant lymphoma, non-Hodgkin's (1172592001); Non-Hodgkin lymphoma (1172592001); Non-Hodgkin's lymphoma (1172592001); Non-Hodgkin malignant lymphoma (1172592001); Non-Hodgkin's malignant lymphoma (1172592001)
 
Related genes: RAD54B, BCL10, RAD54L, PRF1, CASP10
 
HPO: HP:0012539
Monarch Initiative: MONDO:0018908
OMIM®: 191170
Orphanet: ORPHA547

Definition

A type of lymphoma characterized microscopically by the absence of multinucleated Reed-Sternberg cells. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
Follow this link to review classifications for Non-Hodgkin lymphoma in Orphanet.

Conditions with this feature

Ataxia-telangiectasia syndrome
MedGen UID:
439
Concept ID:
C0004135
Disease or Syndrome
The phenotypic spectrum of ataxia-telangiectasia (A-T), a multisystem disorder, is a continuum ranging from classic A-T at the severe end and variant A-T at the milder end. Nonetheless, distinguishing between classic A-T and variant A-T on this spectrum helps understand differences in disease course, rate of progression, and life expectancy. Classic A-T is characterized by childhood onset of progressive neurologic manifestations (initially cerebellar ataxia, followed typically by extrapyramidal involvement and peripheral sensorimotor neuropathy), immunodeficiency (variably associated with abnormalities of humoral immunity, cellular immunity, or combined immune deficiency), pulmonary disease (resulting from recurrent infections, immune deficiency, aspiration, interstitial lung disease, and neurologic abnormalities), and increased risk of malignancy. Although it is generally accepted that intellectual disability is not common in A-T, disturbances in cerebellar as well as non-cerebellar brain areas and networks may result in cognitive deficits. Increased sensitivity to ionizing radiation (x-ray and gamma ray) can result in severe side effects from such treatments. Life expectancy is significantly reduced due to cancer, pulmonary disease, and infections. Variant A-T has a significantly milder disease course. While cerebellar ataxia can be absent, extrapyramidal movement disorders are common (typically dystonia and dystonic tremor) and most individuals have manifestations of axonal sensorimotor polyneuropathy. In contrast to classic A-T, immune function is generally normal, respiratory infections are not increased, and pulmonary disease is not a major feature. However, risk of developing malignancies is increased, particularly in premenopausal females who have an increased risk of developing breast cancer and hematologic malignancies.
Leukemia/lymphoma, b-cell, 2
MedGen UID:
854626
Concept ID:
C3887918
Neoplastic Process
Mismatch repair cancer syndrome 1
MedGen UID:
1748029
Concept ID:
C5399763
Disease or Syndrome
Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.
Mismatch repair cancer syndrome 4
MedGen UID:
1745382
Concept ID:
C5436817
Disease or Syndrome
Mismatch repair cancer syndrome-4 (MMRCS4) is an autosomal recessive childhood cancer predisposition syndrome characterized by early-onset leukemia/lymphoma, brain tumors, colorectal/gastrointestinal cancers, and other rare malignancies, including rhabdomyosarcoma (summary by Li et al., 2015). Cafe-au-lait spots are usually present (De Vos et al., 2006). For a discussion of genetic heterogeneity of mismatch repair cancer syndrome, see MMRCS1 (276300).

Professional guidelines

PubMed

Lewis WD, Lilly S, Jones KL
Am Fam Physician 2020 Jan 1;101(1):34-41. PMID: 31894937
Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T
Dtsch Arztebl Int 2017 May 26;114(20):354-361. doi: 10.3238/arztebl.2017.0354. PMID: 28610655Free PMC Article
Matasar MJ, Zelenetz AD
Radiol Clin North Am 2008 Mar;46(2):175-98, vii. doi: 10.1016/j.rcl.2008.03.005. PMID: 18619375

Recent clinical studies

Etiology

Pearce L
Nurs Stand 2016 Sep 14;31(3):15. doi: 10.7748/ns.31.3.15.s16. PMID: 27745040
Kumar A, Sundararajan S, Puvvada S, Persky DO
Curr Treat Options Oncol 2016 Sep;17(9):45. doi: 10.1007/s11864-016-0424-2. PMID: 27423794
Shad A, Magrath I
Pediatr Clin North Am 1997 Aug;44(4):863-90. doi: 10.1016/s0031-3955(05)70534-4. PMID: 9286289
Hancock BW
J R Coll Physicians Lond 1995 Jul-Aug;29(4):340-3. PMID: 7473331Free PMC Article
Graham M
Pediatr Ann 1988 Mar;17(3):192-3, 197-203. doi: 10.3928/0090-4481-19880301-08. PMID: 3281105

Diagnosis

Pearce L
Nurs Stand 2016 Sep 14;31(3):15. doi: 10.7748/ns.31.3.15.s16. PMID: 27745040
Ansell SM
Mayo Clin Proc 2015 Aug;90(8):1152-63. doi: 10.1016/j.mayocp.2015.04.025. PMID: 26250731
Shankland KR, Armitage JO, Hancock BW
Lancet 2012 Sep 1;380(9844):848-57. Epub 2012 Jul 25 doi: 10.1016/S0140-6736(12)60605-9. PMID: 22835603
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N
J Natl Compr Canc Netw 2011 May;9(5):484-560. doi: 10.6004/jnccn.2011.0046. PMID: 21550968
Patte C
Eur J Cancer 1998 Feb;34(3):359-62; discussion 362-3. doi: 10.1016/s0959-8049(97)10142-3. PMID: 9640222

Therapy

Grommes C, DeAngelis LM
J Clin Oncol 2017 Jul 20;35(21):2410-2418. Epub 2017 Jun 22 doi: 10.1200/JCO.2017.72.7602. PMID: 28640701Free PMC Article
Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM
J Natl Cancer Inst 2017 Mar;109(3) Epub 2016 Dec 31 doi: 10.1093/jnci/djw255. PMID: 28040699Free PMC Article
Sujobert P, Rioufol C, Salles GA
Cancer J 2016 Jan-Feb;22(1):12-6. doi: 10.1097/PPO.0000000000000167. PMID: 26841011
DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P
Nat Rev Drug Discov 2009 Feb;8(2):105-6. doi: 10.1038/nrd2819. PMID: 19180104
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma
J Clin Oncol 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22 doi: 10.1200/JCO.2006.09.2403. PMID: 17242396

Prognosis

Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD
Lancet Oncol 2016 Aug;17(8):1081-1093. Epub 2016 Jun 23 doi: 10.1016/S1470-2045(16)30097-3. PMID: 27345636
Patte C
Eur J Cancer 1998 Feb;34(3):359-62; discussion 362-3. doi: 10.1016/s0959-8049(97)10142-3. PMID: 9640222
Hancock BW
J R Coll Physicians Lond 1995 Jul-Aug;29(4):340-3. PMID: 7473331Free PMC Article
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877
Misra A, Kapur BM, Rath GK
J Surg Oncol 1991 Aug;47(4):265-70. doi: 10.1002/jso.2930470412. PMID: 1861497

Clinical prediction guides

Zanoni L, Bezzi D, Nanni C, Paccagnella A, Farina A, Broccoli A, Casadei B, Zinzani PL, Fanti S
Semin Nucl Med 2023 May;53(3):320-351. Epub 2022 Dec 14 doi: 10.1053/j.semnuclmed.2022.11.001. PMID: 36522191
Kim B, Raphael B, Liu C, Golden BD
Bull Hosp Jt Dis (2013) 2019 Dec;77(4):275-278. PMID: 31785142
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE
Ann Oncol 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. PMID: 28379322Free PMC Article
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute
J Clin Oncol 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. PMID: 25113753Free PMC Article
Zucca E, Conconi A, Cavalli F
Best Pract Res Clin Haematol 2002 Sep;15(3):533-47. doi: 10.1053/beha.2002.0218. PMID: 12468404

Recent systematic reviews

Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, Rowley S, Saad A, Goy A, Dunleavy K, Ali A
Blood Adv 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525. PMID: 36260735Free PMC Article
Zhong H, Liu S, Wang Y, Xu D, Li M, Zhao Y, Zeng X
Autoimmun Rev 2022 May;21(5):103084. Epub 2022 Mar 24 doi: 10.1016/j.autrev.2022.103084. PMID: 35341972
Yasuda H, Yasuda M, Komatsu N
Cancer Sci 2021 Jul;112(7):2607-2624. Epub 2021 Jun 11 doi: 10.1111/cas.14933. PMID: 33938097Free PMC Article
Zhang L, Rana I, Shaffer RM, Taioli E, Sheppard L
Mutat Res Rev Mutat Res 2019 Jul-Sep;781:186-206. Epub 2019 Feb 10 doi: 10.1016/j.mrrev.2019.02.001. PMID: 31342895Free PMC Article
Xu J, Wang T
Hematology 2019 Dec;24(1):527-532. doi: 10.1080/16078454.2019.1636485. PMID: 31262228

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...